Compare Regions Financial Corporation Common Stock (RF) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regions Financial Corporation Common Stock vs Tango Therapeutics Inc. — how do they compare? Regions Financial Corporation Common Stock trades at $26.93 (market cap $23.01B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Regions Financial Corporation Common Stock is far larger — about 6.1× Tango Therapeutics Inc.'s market cap, and Regions Financial Corporation Common Stock pays a 4.05% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regions Financial Corporation Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| RF | TNGX | |
|---|---|---|
Market Cap | $23.01B | $3.75B |
Volume | 10,095,088 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $32.40 | $32.90 |
52-Week Low | $23.35 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $20.75B | $2.77B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regions Financial (RF) trades at $27.01, down 1.32% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 10.98, net income margin of 29.3%, and consistent earnings beats in recent quarters. Recent news highlights dividend declarations and upcoming Q3 earnings, while the company plans significant branch expansion.
The outlook is cautiously optimistic with a $32.78 consensus price target suggesting 21% upside. Key risks include elevated expenses and weaker capital markets revenue. Analyst sentiment is mixed with 40% buy ratings, but institutional interest remains strong with Bank of America's recent $219 million investment.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regions Financial Corporation Common Stock
Regions Financial is a financial holding company that operates through Regions Bank. It provides consumer, commercial, mortgage, wealth-management, and investment services across the South, Midwest, and Texas.
Read more on RF →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
